Anacor Reports Positive Preliminary Results From Crisaborole Phase 3 Trials

(RTTNews) - Anacor Pharmaceuticals, Inc. (ANAC) announced preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The company said, in both studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies.

The Phase 3 pivotal studies of crisaborole consisted of two multi-center, double-blind, vehicle-controlled studies of over 750 patients each, aged 2 years and older with mild-to-moderate atopic dermatitis.

Anacor Pharma currently plans to file a New Drug Application for crisaborole in the first half of 2016.